Discover
mirikizumab (LY3074828) / Eli LillyVIVID-2: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (clinicaltrials.gov) - Jan 18, 2020 - P3; N=778; Not yet recruiting; Sponsor: Eli Lilly and Company
filgotinib (GLPG0634) / GileadFilgotinib US regulatory estimate: Submission for ulcerative colitis in H2 2020 (Wells Fargo) - Jan 18, 2020 - A subscription to Thomson ONE is required to gain full access to report 68595639; Page no: 21; REPORT TITLE: "Biotech sector outlook - Fundamental/strategic value outweighs E"; AUTHOR: Birenchenough, James, et al; DATE: 01/05/2020
etrasimod (APD334) / ArenaEtrasimod: Data from P3 trial for Crohn’s disease in 2022 (Arena) - Jan 16, 2020 - Corporate PresentationP3 data[Screenshot]
etrasimod (APD334) / ArenaEtrasimod: Completion of enrollment of P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in 2020 (Arena) - Jan 16, 2020 - Corporate Presentation: Data from P3 ELEVATE UC 12 trial (NCT03996369) for ulcerative colitis in 2021 [Screenshot]
etrasimod (APD334) / ArenaEtrasimod: NDA submission for ulcerative colitis in 2022 (Arena) - Jan 16, 2020 - Corporate Presentation [Screenshot]
etrasimod (APD334) / ArenaA study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease (clinicaltrialsregister.eu) - Jan 16, 2020 - P2; N=225; Ongoing; Sponsor: Arena Pharmaceuticals Inc.
Entyvio (vedolizumab) / TakedaTakeda’s Quintiles [sic] expands indication for ulcerative colitis, Crohn’s disease (Korea Biomedical Review) - Jan 17, 2020 - "The Ministry of Food and Drug Safety recently granted the nod to Quintiles [sic] (ingredient: vedolizumab) as the first-line therapy for ulcerative colitis and Crohn’s disease....In recent trials, Quintiles [sic] showed statistically superior clinical remission, compared to existing TNF-alpha inhibitors."
Humira (adalimumab) / Eisai, AbbVieEfficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jan 15, 2020 - P3; N=101; Completed; Sponsor: AbbVie; Active, not recruiting --> Completed; Trial completion date: Sep 2020 --> Dec 2019; Trial primary completion date: Jun 2020 --> Dec 2019
Humira (adalimumab) / Eisai, AbbVieEfficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jan 18, 2020 - P3; N=101; Active, not recruiting; Sponsor: AbbVie; Completed --> Active, not recruiting
Xeljanz (tofacitinib) / PfizerXeljanz patent expiry: Late 2025 in US (RBC Capital Markets (Canada)) - Jan 17, 2020 - A subscription to Thomson ONE is required to gain full access to report 68599422; Page no: 13; REPORT TITLE: "Pfizer Inc. - P&L to inflect off more innovative high growth base; Initiate at OP, $46 target"; AUTHOR: Stanicky, Randall, et al; DATE: 01/06/2020
